We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
William Sandborn

William J. Sandborn MD

Professor of Medicine; Adjunct Professor of Surgery, University of California; Director, IBD Center; Chief, Division of Gastroenterology, UC San Diego Health System, San Diego, California

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.  He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System.  Dr. Sandborn has published over 487 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease. 

Disclosures

Dr. Sandborn has received consulting fees from or performed contracted research for Janssen, Abbvie, UCB Pharma, Takeda, Pfizer, Amgen, Genentech, Receptos, Actavis, Shire, Salix, Prometheus Laboratories in the past 12 months.